Menu
Search
|

Menu

Close
X

TherapeuticsMD Inc TXMD.OQ (NASDAQ Stock Exchange Global Select Market)

5.58 USD
+0.06 (+1.09%)
As of Feb 16
chart
Previous Close 5.52
Open 5.49
Volume 413,179
3m Avg Volume 649,632
Today’s High 5.61
Today’s Low 5.46
52 Week High 8.29
52 Week Low 3.50
Shares Outstanding (mil) 216.43
Market Capitalization (mil) 1,207.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY17
13
FY16
19
FY15
20
EPS (USD)
FY17
-0.274
FY16
-0.458
FY15
-0.494
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
70.46
8.57
Price to Book (MRQ)
vs sector
8.08
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
-52.96
13.54
Return on Equity (TTM)
vs sector
-52.96
14.80

EXECUTIVE LEADERSHIP

Tommy Thompson
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
John Milligan
President, Secretary, Director, Since 2011
Salary: $450,000.00
Bonus: --
Robert Finizio
Chief Executive Officer, Director, Since 2012
Salary: $600,000.00
Bonus: $50,000.00
Daniel Cartwright
Chief Financial Officer, Treasurer, Since 2015
Salary: $375,000.00
Bonus: --
Mitchell Krassan
Executive Vice President, Chief Strategy Officer, Since 2011
Salary: $300,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

6800 Broken Sound Pkwy NW
BOCA RATON   FL   33487-2721

Phone: +1561.9611911

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

SPONSORED STORIES